Furthermore, the identified luteolin-4′-O-glucoside and luteolin could be promising XO inhibitors for clinical use in the prevention and treatment of gout and hyperuricemia and to verify this further in vivo studies are being carried out. This evidence concerns the gene XDH and gout.